Project Grant R33CA309789
Award Date 5/1/26
Completion Date 4/30/29
Dollars Obligated $396K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Atlanta, GA 30332, USA
Similar Awards
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded Georgia State University Research Foundation Inc. a $406,258 Project Grant on July 15, 2025, under the Cancer Treatment Research program (CFDA 93.395) to develop novel covalent anti-cancer drugs utilizing phosphorus fluoride exchange (PFEX) click chemistry. The two-year research initiative, concluding June 30, 2027, focuses on designing privileged covalent warheads with expanded target scopes to overcome limitations of...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded Harvard College's Office for Sponsored Programs a Project Grant of $604,102 under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) to develop innovative three-dimensional (3D) bioprinted vascular cancer models. The five-year project, which commenced May 1, 2026 and concludes April 30, 2031, will deliver in vitro human and murine cancer models utilizing microporous embedded printing technology to enable...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded The Johns Hopkins University a Project Grant totaling $144,193 under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) on September 4, 2025, with a completion date of August 31, 2030. This award provides protected salary support for Dr. Preethi Korangath, a Laboratory Research Specialist in Dr. Robert Ivkov's laboratory, to advance research in cancer detection and treatment technologies. Dr. Korangath will...
- Federal Grant Award Summary The National Cancer Institute awarded The Institute For Cancer Research a $186,000 Project Grant under the Cancer Treatment Research program (CFDA 93.395) on June 23, 2025, with a completion date of May 31, 2027. The award supports pilot and feasibility studies for NN-01-195, a novel tumor-targeted Aurora-A kinase (AURKA) inhibitor developed through a drug conjugate approach. The research involves preclinical evaluation of this chimeric compound, which fuses an...
- Federal Grant Award Summary The National Cancer Institute awarded $138,846 to the University Health Network under the Cancer Detection and Diagnosis Research program (CFDA 93.394) for a two-year Project Grant commencing August 1, 2025 and concluding July 31, 2027. The award supports the development of laboratory-generated "wild-like" mouse models designed to enhance the translational relevance of preclinical cancer and immunotherapy research. The primary deliverable involves adapting...
- Federal Project Grant Award Summary Emory University received a $402,401 Project Grant award from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394), effective May 6, 2026, with a completion date of April 30, 2028. The award supports the development of an 18F-labeled positron emission tomography (PET) imaging agent capable of detecting and measuring isocitrate dehydrogenase 1 mutant (IDH1-R132H) expression in gliomas. This exploratory...
- Federal Grant Award Summary The National Cancer Institute awarded a $371,024 Project Grant to Wayne State University under the Cancer Biology Research program (CFDA 93.396) effective April 1, 2026 through March 31, 2031. This five-year award supports fundamental research investigating the noncanonical signaling mechanisms of Janus Kinase 1 (JAK1) and Janus Kinase 2 (JAK2) in mammary gland development and breast cancer. The research project aims to elucidate the biological roles of JAK1 and...
- Federal Grant Award Summary Daignostx L.L.C. received a $306,798 Phase I Small Business Technology Transfer (STTR) award from the National Cancer Institute under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) effective September 1, 2025, through August 31, 2026. The company will develop critical system components for an artificial intelligence (AI)-based lymph node (LN) malignancy classification platform designed to improve cancer treatment planning. The deliverables...
- Federal Project Grant Award Summary Case Western Reserve University received $630,108 in Project Grant funding from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394), awarded March 13, 2026, with a completion date of February 28, 2030. The award supports theranostic research developing combined fluorescence image-guided surgery (FIGS) and photothermal therapy (PTT) approaches for breast cancer treatment. The research centers on optimizing...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded the University of Alabama a $631,621 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop an integrated top-down proteomics and phosphoproteomics platform for analyzing patient-derived ovarian cancer spheroids. The award, effective August 13, 2025, through July 31, 2028, supports the creation of personalized intact proteome maps that characterize disease states and identify markers...